TYME - タイム・テクノロジ―ズ (Tyme Technologies Inc.)

TYMEのニュース

   Tyme Technologies, Inc. (NASDAQ:TYME) Major Shareholder Michael Demurjian Sells 20,000 Shares of Stock  2021/02/18 12:04:41 Watchlist News
Tyme Technologies, Inc. (NASDAQ:TYME) major shareholder Michael Demurjian sold 20,000 shares of the business’s stock in a transaction dated Tuesday, February 16th. The shares were sold at an average price of $2.77, for a total value of $55,400.00. Following the completion of the transaction, the insider now directly owns 24,858,546 shares of the company’s stock, […]
   Why Tyme Technologies Stock Is Taking Off Today | The Motley Fool  2021/02/09 17:00:00 Flipboard
The company closed a $100 million public stock offering.
   TYME Announces Closing of $100 Million Registered Direct Offering of Common Stock  2021/02/08 17:46:00 Business Wire
BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that today it closed its previously announced registered direct offering of 40,000,000 shares of its common stock, par value $0.0001 per share, at a purchase price of $2.50 per share, priced at-the-market under Nasdaq rules. The gross proceeds of the offering were $100 million, prior to deducting placement agent’s fees and
   Tyme Technologies (NASDAQ:TYME) Issues Quarterly Earnings Results  2021/02/06 15:23:10 Transcript Daily
Tyme Technologies (NASDAQ:TYME) announced its quarterly earnings data on Thursday. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01, Fidelity Earnings reports. TYME opened at $2.38 on Friday. The stock has a fifty day moving average of $1.62 and a 200-day moving average of $1.20. The company has […]
   TYME Provides Business Update and Announces Third Quarter Fiscal 2021 Financial and Operating Results  2021/02/04 13:00:00 Business Wire
BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its third quarter ended December 31, 2020. During the quarter, TYME continued to build its leadership team with the announcement of Richie Cunningham as the new CEO; the Company continued to grow its global patent portfolio; expanded its body of peer-reviewed data presentations on SM-88 (
   Tyme Technologies, Inc. (NASDAQ:TYME) Major Shareholder Michael Demurjian Sells 20,000 Shares of Stock  2021/02/18 12:04:41 Watchlist News
Tyme Technologies, Inc. (NASDAQ:TYME) major shareholder Michael Demurjian sold 20,000 shares of the business’s stock in a transaction dated Tuesday, February 16th. The shares were sold at an average price of $2.77, for a total value of $55,400.00. Following the completion of the transaction, the insider now directly owns 24,858,546 shares of the company’s stock, […]
   Why Tyme Technologies Stock Is Taking Off Today | The Motley Fool  2021/02/09 17:00:00 Flipboard
The company closed a $100 million public stock offering.
   TYME Announces Closing of $100 Million Registered Direct Offering of Common Stock  2021/02/08 17:46:00 Business Wire
BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that today it closed its previously announced registered direct offering of 40,000,000 shares of its common stock, par value $0.0001 per share, at a purchase price of $2.50 per share, priced at-the-market under Nasdaq rules. The gross proceeds of the offering were $100 million, prior to deducting placement agent’s fees and
   Tyme Technologies (NASDAQ:TYME) Issues Quarterly Earnings Results  2021/02/06 15:23:10 Transcript Daily
Tyme Technologies (NASDAQ:TYME) announced its quarterly earnings data on Thursday. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01, Fidelity Earnings reports. TYME opened at $2.38 on Friday. The stock has a fifty day moving average of $1.62 and a 200-day moving average of $1.20. The company has […]
   TYME Provides Business Update and Announces Third Quarter Fiscal 2021 Financial and Operating Results  2021/02/04 13:00:00 Business Wire
BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its third quarter ended December 31, 2020. During the quarter, TYME continued to build its leadership team with the announcement of Richie Cunningham as the new CEO; the Company continued to grow its global patent portfolio; expanded its body of peer-reviewed data presentations on SM-88 (
   Tyme Technologies, Inc. (NASDAQ:TYME) Major Shareholder Michael Demurjian Sells 20,000 Shares of Stock  2021/02/18 12:04:41 Watchlist News
Tyme Technologies, Inc. (NASDAQ:TYME) major shareholder Michael Demurjian sold 20,000 shares of the business’s stock in a transaction dated Tuesday, February 16th. The shares were sold at an average price of $2.77, for a total value of $55,400.00. Following the completion of the transaction, the insider now directly owns 24,858,546 shares of the company’s stock, […]
   Why Tyme Technologies Stock Is Taking Off Today | The Motley Fool  2021/02/09 17:00:00 Flipboard
The company closed a $100 million public stock offering.
   TYME Announces Closing of $100 Million Registered Direct Offering of Common Stock  2021/02/08 17:46:00 Business Wire
BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that today it closed its previously announced registered direct offering of 40,000,000 shares of its common stock, par value $0.0001 per share, at a purchase price of $2.50 per share, priced at-the-market under Nasdaq rules. The gross proceeds of the offering were $100 million, prior to deducting placement agent’s fees and
   Tyme Technologies (NASDAQ:TYME) Issues Quarterly Earnings Results  2021/02/06 15:23:10 Transcript Daily
Tyme Technologies (NASDAQ:TYME) announced its quarterly earnings data on Thursday. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01, Fidelity Earnings reports. TYME opened at $2.38 on Friday. The stock has a fifty day moving average of $1.62 and a 200-day moving average of $1.20. The company has […]
   TYME Provides Business Update and Announces Third Quarter Fiscal 2021 Financial and Operating Results  2021/02/04 13:00:00 Business Wire
BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its third quarter ended December 31, 2020. During the quarter, TYME continued to build its leadership team with the announcement of Richie Cunningham as the new CEO; the Company continued to grow its global patent portfolio; expanded its body of peer-reviewed data presentations on SM-88 (

calendar